InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Dahms Bradford D., Chief Financial Officer. Officer active across 2 companies, notably Theseus Pharmaceuticals, Inc.. Aggregated, 4 reports have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €27k. Activity tracked since 21 December 2021. The latest transaction was disclosed on 12 February 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations4 total
37,813 shares0Common StockSEC:0001193125-26-052056:0
8,150.225 sharesCommon StockSEC:0001104659-24-023551:0
1,502.189 shares@ US$6.65721.5% of flowCommon StockSEC:0001104659-22-123686:0
Ideal exit: 27 Aug 2023 (T+270)
1,970.036 shares@ US$10.152150.0% of flowCommon StockSEC:0000899243-21-049427:0
Ideal exit: 17 Sept 2022 (T+270)
4 of 4 declarations
About Dahms Bradford D.
Bradford D. Dahms serves as Chief Financial Officer at Theseus Pharmaceuticals, Inc. In this role, he oversees the company's financial operations, including financial planning and reporting. Bradford has significant experience in finance, enabling him to contribute to the company's financial strategy. His analytical approach is essential for navigating a complex financial environment.
